How Pulmozyme works to fight cystic fibrosis (CF)

It works to fight CF, even when you can’t feel it

In clinical studies, Pulmozyme (dornase alfa) made mucus thinner and looser, which can make it easier to clear your lungs. CF often requires several different medicines as part of a treatment routine. Not all medicines work the same, so your doctor will prescribe multiple therapies to help you fight CF.

How Pulmozyme works to fight cystic fibrosis

Laboratory studies show that Pulmozyme (dornase alfa) cuts apart extracellular DNA by acting like an enzyme* naturally found in the lungs. By cutting this extracellular DNA, Pulmozyme helps make the thick, sticky mucus that your lungs produce thinner and looser.

*Enzymes are proteins created by the body to help speed up chemical reactions (such as the breakdown of molecules).

Why is Pulmozyme important?

In cystic fibrosis, your lungs produce extra-thick, sticky mucus. In laboratory studies, Pulmozyme (dornase alfa) made this mucus thinner and looser.

Cystic Fibrosis (CF) mucus before Pulmozyme® (dornase alfa)
CF mucus before Pulmozyme
Cystic Fibrosis (CF) mucus after Pulmozyme® (dornase alfa)
CF mucus after Pulmozyme

A study of cystic fibrosis patients 5 years of age and older with a forced vital capacity (FVC) of greater than or equal to 40% of predicted found:

Lung infections

Patients taking Pulmozyme daily had a lower risk of developing lung infections requiring intravenous (IV) antibiotics and showed an improvement in lung function, compared with those not taking Pulmozyme.

Starting treatment with Pulmozyme

Before taking your Pulmozyme (dornase alfa), it is important to receive training from your CF Care Team. Here's what you will need to get started:

  • Your Pulmozyme dose
  • Nebulizer
  • Compressor

Discussing Pulmozyme with your doctor

Use this Discussion Guide to help prepare for your doctor’s appointment and get the answers you’ll need for your everyday Pulmozyme treatment.

Financial assistance

Need help paying for Pulmozyme?

Get info on our financial support programs

Getting started with Pulmozyme® (dornase alfa)

Getting started on Pulmozyme?

Learn about what you need to do to prepare for treatment

Important Safety Information

Indication and Usage

Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.